Glomerulonephritis can be exacerbated by infection. This study investigated the effect of N-palmitoyl-S-(2,3-bis(palmitoyloxy)-(2R,S)-propyl)-(R)-cysteinyl-seryl-(lysyl)3-lysine (Pam 3 CysSK 4 ), a synthetic Toll-like receptor 2 (TLR2) ligand, that was given at immunization on disease severity in accelerated nephrotoxic nephritis. Stimulation of TLR by microbial constituents is known to influence the development of the adaptive immunity. It was hypothesized that the TLR2 ligand Pam 3 CysSK 4 can modulate the development of disease in accelerated nephrotoxic nephritis by influencing the development of adaptive immunity. It is shown that Pam 3 CysSK 4 , when given at immunization, can increase profoundly the severity of disease, and with the use of TLR2-deficient mice, it is shown that this disease exacerbation depends on the presence of TLR2. Wild-type mice that were given Pam 3 CysSK 4 at immunization and had more severe disease also had a greater amount of antigen-specific IgG1, IgG2b, and IgG3 in the serum and more IgG2b and IgG3 deposited within the glomerulus. They also had increased numbers of glomerular CD4-positive T cells. Therefore, the more severe disease that was seen in the group that was immunized with lipopeptide can be attributed to an influence on the adaptive immune response.
G lomerulonephritis in humans can be exacerbated by infection. For example, in IgA nephropathy, an upper respiratory tract infection commonly precedes episodes of hematuria (1) . In addition, relapses of anti-neutrophil cytoplasmic antibody-associated vasculitis are associated with the nasal carriage of Staphylococcus aureus (2, 3) , and exacerbations of anti-glomerular basement membrane disease can be attributed to infective episodes (4) . A variety of infectious organisms, including both bacteria and viruses, may contribute to the exacerbation of disease in glomerulonephritis. Toll-like receptor 2 (TLR2) is one of a family of 11 described receptors that are responsible for recognizing pathogens and initiating an immune response (5, 6) . TLR2, in particular, recognizes constituents of Gram-positive and Gram-negative bacteria (5) and not only affects the initial innate immune response but also has a role in the control of adaptive immunity (7, 8) .
Pathogen recognition by TLR promotes the production of proinflammatory cytokines and acute inflammation by recruitment of inflammatory cells to the site of infection by activation of local stromal cells and circulating leukocytes (9, 10) . It also has been demonstrated that activation of dendritic cells by specific TLR ligands can influence the development of an adaptive immune response both in vivo (7) and in vitro (11) (12) (13) . TLR2 can be found on professional immune cells, including neutrophils, macrophages, and dendritic cells, but also on stromal cells throughout the body (14) . Within the kidney, mRNA for TLR2 has been isolated from mouse renal tubular epithelial cells, and in situ hybridization has shown the presence of TLR2 in tubular epithelial cells and also within the glomerulus (15, 16) .
TLR2 recognizes pathogen-associated molecular patterns that are associated with both Gram-negative and Gram-positive bacteria, including lipopeptide, peptidoglycan, and lipoteichoic acid (5) . The synthetic compound N-palmitoyl-S-(2,3-bis(palmitoyloxy)-(2R,S)-propyl)-(R)-cysteinyl-seryl-(lysyl)3-lysine (Pam 3 CysSK 4 ) is a triacylated lipopeptide that mimics the activity of naturally occurring triacylated lipopeptides (17) . It is a specific ligand for TLR2 in human (18) and mouse cells (19) . TLR2 dimerizes with TLR1 and TLR6, and these different interactions are associated with discrimination between different microbial constituents. In the case of Pam 3 CysSK 4 , recognition is mediated by TLR2 dimerized with TLR1 (19) .
There are two main ways in which TLR ligands may affect the development of glomerulonephritis: (1) By an effect on the innate immune system and subsequent inflammatory response that may be mediated by leukocytes or intrinsic renal cells and (2) by modulation of the adaptive immune response by influencing the maturation of dendritic cells and subsequent activation of sensitized T cells. In this study, we investigated the latter of these two mechanisms using the animal model of accelerated nephrotoxic nephritis. This is an established model of immunemediated glomerular injury, whereby an immune response is generated against a foreign antibody that is bound to the glomerular basement membrane. The resulting glomerular injury is characterized by glomerular hypercellularity, thrombosis, and crescent formation and is accompanied by proteinuria.
Previous work using similar models of glomerular injury has shown that the disease is T cell mediated and associated with a systemic immune response predominantly of the Th1 type (20 -23) . In particular, it has been shown that the disease is mediated by the Th1 cytokine IFN-␥ (21), and administration of Th2 cytokines such as IL-4 can attenuate disease (20) . It is likely that specific types of human glomerulonephritis are associated with a polarization in the T cell response. For example, studies of human crescentic glomerulonephritis have shown that there is a predominant macrophage, T cell, and fibrin deposition that is consistent with a predominant Th1-type immune response (24, 25) , whereas in membranous nephropathy, there is IgG4 deposition within the glomerulus, an IgG subclass that is associated with a Th2 immune response (26) .
We investigated the role of the synthetic lipopeptide Pam 3 CysSK 4 in the mediation of disease using TLR2-deficient mice and explored whether this is associated with a modulation of the immune response. We show that disease can be exacerbated by lipopeptide and that the disease exacerbation is mediated by TLR2. In addition, we show that the increase in disease severity is associated with an augmented adaptive immune response.
Materials and Methods

Mice
TLR2-deficient mice (backcrossed seven generations to C57BL/6) were constructed by and obtained from S. Akira (27) , and appropriate age-, gender-, and weight-matched wild-type C57BL/6 mice were obtained from Harlan (Bicester, Oxon, UK). All mice used were 9 to 10 wk of age at commencement of the experiments. Animal experiments were performed according to Home Office regulations. The genotype of the TLR2-deficient mice was confirmed by PCR.
Induction of Accelerated Nephrotoxic Nephritis
A mouse glomerular extract was made as described previously (28) , and serum was prepared in sheep by Micropharm (Llandysul, UK). The nephrotoxic serum (NTS) was heat inactivated at 56°C for 30 min and frozen in aliquots at Ϫ20°C until use.
Mice were immunized intraperitoneally with 200 g of normal sheep IgG that was given with 80 l of aluminum hydroxide gel (Sigma, Poole, UK) in 310 l of PBS, with 100 g of Pam 3 CysSK 4 (EMC Microcollections, Tü bingen, Germany) in 10 l of DMSO or with 10 l of DMSO alone. All of these components were given as a single intraperitoneal injection. Five days later, mice received an injection of 160 l of NTS via the tail vein to induce disease. The dose of lipopeptide and NTS given were based on those used in other in vivo studies and on our own pilot studies (13) . At 14 d after disease induction, mice were killed and exsanguinated for serum, and the kidneys were harvested. Any mice that showed signs of ill health before 14 d were killed humanely according to local regulations.
Histologic Analysis of Glomerular Injury
Kidney samples were fixed for 4 h in Bouin's solution, transferred into formalin, then processed and embedded in paraffin. Sections were cut at 0.5 m thickness and stained with periodic acid-Schiff (PAS) reagent. All samples then were assessed blindly for glomerular thrombosis by identification of the amount of PAS-positive material. In total, 50 glomeruli were assessed for each mouse for signs of glomerular thrombosis, and a score was assigned to each as follows: Grade 0, no PAS-positive material; grade 1, Ͻ25%; grade 2, 25 to 50%, grade 3, 50 to 75%, and grade 4, 75 to 100%. The average glomerular thrombosis score for each mouse then was calculated. Sections also were assessed blindly for glomerular crescents. A total of 50 glomeruli were assessed, and the number of crescents (two or more layers of cells in Bowman's space) was expressed as a percentage.
Immunohistochemical Analysis for Glomerular Macrophages and CD4 T Cells
For macrophage staining, kidney samples were snap-frozen in cold isopentane, with sections fixed in acetone. For CD4 T cell staining, kidney was fixed in phosphate-lysine-periodate for 4 h at 4°C and transferred to 13% sucrose before freezing. Endogenous peroxidase was blocked by immersing slides in 0.3% H 2 O 2 in methanol for 10 min. Endogenous biotin was blocked using an avidin/biotin blocking kit 
Serum Creatinine
The serum creatinine was measured on samples that were collected at day 14 by mass spectometry using Applied Biosystems MDS Sciex API 4000 (Applied Biosystems, Warrington, UK) and the software Applied Biosystems Analysis Version 1.4.
Albuminuria
Mice were housed in metabolic cages for 24 h for urine collections. The urine albumin concentration was measured by radial immunodiffusion as described previously (28) . The sensitivity of the radial immunodiffusion assay for albumin was 0.05 mg/ml. Urine samples were diluted to 1:40 so that values fell on the standard curve.
Measurement of Glomerular Sheep IgG Deposition
Snap-frozen sections (described above) were cut to 5 m thickness. After fixation in ice-cold acetone for 10 min, sections were incubated with a directly FITC-conjugated donkey anti-sheep IgG antibody (Jackson Immunoresearch Laboratories) diluted at 1:100. For quantification of the glomerular deposition of the sheep IgG, images were saved from 20 glomeruli for each mouse. Adobe Photoshop software version 8.0 (Adobe Systems, San Jose, CA) was used to analyze the images. The images were converted to gray scale, and using the lasso tool, each individual glomerulus was drawn around. The mean intensity for each glomerulus was measured using the histogram tool. Quantitative immunofluorescence is established as a reproducible technique for quantifying glomerular proteins and is prone to less variation than graded scoring techniques (29) .
Glomerular Deposition of Mouse IgG Subclasses
Snap-frozen kidney samples were cut at 5 m thickness and fixed in ice-cold acetone for 10 min. FITC-conjugated antibodies were used to detect mouse IgG1, IgG2b, and IgG3 (Southern Biotechnology, Birming-ham, AL) at 1:200 dilution. For assessment of the deposition of IgG2a, a biotinylated anti-mouse IgG2a antibody was used (BD Pharmingen) at 1:100 for 1 h. Slides were washed in PBS, and fluorescein streptavidin (Vector Laboratories) was added at 1:30 for 1 h. For quantification of the glomerular deposition of the murine IgG subclasses, images were saved from 20 glomeruli for each mouse. The mean fluorescence intensity then was measured as described above.
Measurement of Murine IgG Subclasses Specific for Sheep IgG in Serum
The titers of murine IgG subclasses that are specific for sheep IgG were measured by ELISA on serum that was collected at the end of the experiment. Plates were coated with sheep IgG in PBS at 100 g/ml and left overnight at 4°C. Plates were washed, blocked with 1% BSA in PBS, washed again, and then incubated with the sample mouse serum for 1 h. After an additional wash, the bound mouse Ig was detected using an alkaline phosphatase subclass-specific antibody for IgG1, IgG2b, and IgG3 (Southern Biotechnology) all at 1:1000 and pNpp (Sigma-Aldrich Company) used as the substrate. For IgG2a, a biotinconjugated antibody was used to detect the bound mouse Ig (BD Pharmingen) at 1:5000; streptavidin horseradish peroxidase then was added for 30 min, and 3,3Ј,5,5Ј-tetramethylbenzidine (TMB) then was used as the substrate. The relative concentrations were measured using a standard curve that was constructed from pooled serum samples from mice that were immunized with sheep IgG.
Statistical Analyses
Results are expressed showing the mean Ϯ SEM. Statistical differences were assessed using an unpaired t test. When there were more than two groups of data, a one-way ANOVA was used with Tukey post test. Survival data were analyzed using the log-rank test. Tests were performed using GraphPad Prism 4 software (San Diego, CA).
Results
Lipopeptide Exacerbated Accelerated Nephrotoxic Nephritis through a Mechanism Dependent on TLR2
To explore the effect of immunizing with lipopeptide, we compared disease in wild-type and TLR2-deficient mice that were immunized with lipopeptide or vehicle intraperitoneally at the time of immunization with aluminum hydroxide and sheep IgG. Wild-type mice that were immunized with lipopeptide had a significantly worse survival when compared with the wild-type animals that were not immunized with lipopeptide (50% survival compared with 100% survival at 14 d; P ϭ 0.0012; Figure 1 ). The TLR2-deficient mice that were immunized with lipopeptide showed a survival advantage when compared with the wild-type mice that were immunized with lipopeptide, although this did not reach statistical significance (P ϭ 0.098).
All wild-type mice that were culled earlier than day 14 as a result of ill health had features of severe glomerular thrombosis (n ϭ 5; glomerular thrombosis score 190 Ϯ 5.99). Because the glomeruli were almost totally thrombosed, there were very few proliferative changes or crescents. The serum creatinine was markedly elevated in all four animals from which serum was obtained (serum creatinine 146 Ϯ 17 mol/L). The serum creatinine was measured in 19 normal mice for comparison and found to be 14.14 Ϯ 0.29 mol/L. Only mice that survived to day 14 were included in the data analysis. Wild-type mice that were immunized with lipopeptide developed severe glomerular injury, characterized by glomerular thrombosis, crescent formation, and glomerular macrophage infiltration, at 14 d after disease induction. This was associated with an elevated serum creatinine level. When compared with wild-type mice that were not immunized with lipopeptide, there was significantly greater disease as measured by glomerular thrombosis score (P Ͻ 0.05), glomerular crescents (P Ͻ 0.001), and glomerular macrophage infiltration (P Ͻ 0.01; Figures 2 and 3) . The wildtype mice that were immunized with lipopeptide also had more severe renal impairment when compared with the wild-type mice that were not immunized with lipopeptide, as shown by a higher serum creatinine level at day 14 (P Ͻ 0.05; Figure 4 ). Despite the marked differences in glomerular histology, there were no differences in the 24-h albuminuria measured at day 14 in these groups (Figure 4 ). The 24-h albuminuria also was measured in 12 normal mice and found to be undetectable.
In the same experiment, TLR2-deficient mice that were immunized with lipopeptide were significantly protected from disease: TLR2-deficient mice had less glomerular thrombosis, fewer glomerular crescents (Figure 2) , and fewer glomerular macrophages (Figure 3 ) than wild-type mice (P Ͻ 0.001, P Ͻ 0.001, and P Ͻ 0.01, respectively). They also had less functional impairment with lower serum creatinine levels (P Ͻ 0.05; Figure 4) . The albuminuria also was measured at 14 d; however, there was no difference between these two groups ( Figure 4) . These data showed that disease is exacerbated by lipopeptide through a mechanism that depends on TLR2. These differences were apparent even when the five most severely affected wildtype mice and one TLR2-deficient mouse that were given lipopeptide and died before day 14 were excluded from the analysis. Figure 1 . Survival curve of wild-type and Toll-like receptor 2 (TLR2)-deficient mice that were immunized with and without lipopeptide. The survival is significantly worse in the wild-type mice that were given lipopeptide at immunization compared with the wild-type mice that were not immunized with lipopeptide (P ϭ 0.0012). There is a trend toward a worse survival in the wild-type mice that were given lipopeptide at immunization when compared with the TLR2-deficient mice that were given lipopeptide (P ϭ 0.0981).
Differences in Disease Severity between the Groups Was Not Associated with Differences in Sheep IgG Binding in the Glomerulus
To establish that the differences in disease severity were not due to differences in glomerular binding of sheep IgG, immunofluorescence for sheep IgG within the glomerulus was carried out for each mouse at 14 d after disease induction. There was no significant difference in immunofluorescence among any of the groups; the mean for each group was as follows: Wild type, no lipopeptide 65.46 Ϯ 3.6; TLR2 deficient, no lipopeptide 65.98 Ϯ 4.18; wild type, lipopeptide 58.1 Ϯ 5.4; TLR2 deficient, lipopeptide 63.92 Ϯ 4.5.
Immunization with Lipopeptide Was Associated with Higher Serum Levels of Antigen-Specific Ig1, IgG2b, and IgG3
To assess whether the differences in disease that was produced in wild-type and TLR2-deficient mice that were immunized with and without lipopeptide were associated with differences in the systemic immune response to sheep IgG, we measured serum titers of murine IgG subclasses that were specific for sheep IgG and assessed the glomerular deposition of murine IgG subclasses ( Figure 5A) . Initially, the antigenspecific IgG subclasses in the serum were measured at 14 d after disease induction in both wild-type and TLR2-deficient Figure 2 . (A) Glomerular thrombosis score at 14 d after disease induction in wild-type and TLR2-deficient mice that were immunized with and without lipopeptide. There is significantly worse glomerular thrombosis in the wild-type mice that were immunized with lipopeptide compared with the wild-type mice that were not immunized with lipopeptide (P Ͻ 0.01) and the TLR2-deficient mice that were immunized with lipopeptide (P Ͻ 0.001). (B) Percentage of glomerular crescents at 14 d after disease induction in wild-type and TLR2-deficient mice that were immunized with and without lipopeptide. There are significantly greater numbers of crescents in the wild-type mice that were immunized with lipopeptide when compared with the wild-type mice that were not immunized with lipopeptide (P Ͻ 0.001) and TLR2-deficient mice that were immunized with lipopeptide (P Ͻ 0.001). (C) Representative glomerular histology at 14 d after disease induction with nephrotoxic serum in wild-type and TLR2-deficient mice that were immunized with and without lipopeptide. The histology of the wild-type mice that were immunized with lipopeptide shows a glomerular crescent and thrombosis. mice. At this point, there were no consistent differences in the serum levels among any of the groups. An additional experiment therefore was performed in wild-type animals; serum was collected for analysis at 5, 9, and 14 d after disease induction with NTS. At 5 d, there was a significantly greater titer of antigen-specific IgG1, IgG2b, and IgG3 in the serum in the wild-type mice that were immunized with lipopeptide (P ϭ 0.0304, P ϭ 0.0063, and P ϭ 0.0106, respectively). There was no difference in the titers of antigen-specific IgG2a in the serum at 5 d.
Greater Numbers of CD4-Positive T Cells in Glomeruli of Wild-Type Mice Immunized with Lipopeptide
The glomerular CD4 T cell numbers were counted at 14 d after disease induction in wild-type mice that were immunized with or without lipopeptide ( Figure 5 , B and C). Although small numbers were seen, significantly greater numbers were seen in the mice that were immunized with lipopeptide (P ϭ 0.0028).
Immunization with Lipopeptide Was Associated with Higher Glomerular Deposition of IgG2b and IgG3
The glomerular deposition of autologous antibody within the glomerulus also was assessed. Murine IgG2a was barely detectable in the glomeruli of mice in any of the groups, and there was no detectable difference in the IgG1 deposition. There was a significantly greater deposition of IgG2b in the glomeruli of wild-type mice that were given lipopeptide at immunization when compared with the glomeruli of wild-type mice that were not immunized with lipopeptide (P Ͻ 0.05). There was a significantly greater deposition of IgG3 in the glomeruli of wildtype mice that were immunized with lipopeptide when compared with wild-type mice that were not immunized with lipopeptide and TLR2-deficient mice that were immunized with lipopeptide (P Ͻ 0.05 for both comparisons; Figure 6 ).
Discussion
We have shown that lipopeptide, a pure synthetic TLR2 ligand, can exacerbate accelerated nephrotoxic nephritis via a TLR2-dependent mechanism. This is characterized both histologically by a greater glomerular thrombosis score, higher percentage of glomerular crescents, and larger glomerular infiltration by macrophages and well as functionally by higher serum creatinine levels. By using quantitative immunofluorescence for sheep IgG, we excluded one potential explanation. The differences in disease severity are not explained by differences in glomerular sheep IgG binding. The five most severely effected wild-type mice that were given lipopeptide and one TLR2-deficient mouse, which died before day 14, were excluded from the analysis. It is remarkable that even without these mice, clear differences in functional and histologic injury remained.
To investigate whether there were differences in the immune response between the groups, we examined the serum concentrations and the glomerular deposition of murine IgG subclasses. More severe disease in the wild-type mice that were immunized with lipopeptide was associated with higher anti- Figure 4 . (A) Serum creatinine levels in wild-type and TLR2-deficient mice that were immunized with and without lipopeptide. The serum creatinine is significantly higher in the wild-type mice that were immunized with lipopeptide when compared with the wild-type mice that were not immunized with lipopeptide (P Ͻ 0.05) and the TLR2-deficient mice that were immunized with lipopeptide (P Ͻ 0.05). (B) Albuminuria over 24 h at 14 d after disease induction in wild-type and TLR2-deficient mice that were immunized with and without lipopeptide. There is no significant difference between any of the groups. Figure 3. (A) Average number of macrophages per glomerular cross-section at 14 d after disease induction in wild-type and TLR2-deficient mice that were immunized with and without lipopeptide. There were significantly greater numbers of macrophages in the glomeruli of wild-type mice that were immunized with lipopeptide compared with mice that were not immunized with lipopeptide (P Ͻ 0.01) and TLR2-deficient mice that were immunized with lipopeptide (P Ͻ 0.01). (B) Peroxidase staining for CD68 to show glomerular macrophage infiltration at 14 d after disease induction in wild-type and TLR2-deficient mice that were immunized with and without lipopeptide. Greater numbers are seen in the wild-type mice that were immunized with lipopeptide than in any other group.
gen-specific IgG1, IgG2b, and IgG3 at day 5 after disease induction, which was 10 d after immunization. It is important to note that there were no differences in the serum levels of the antigen-specific IgG subclasses at day 14 (19 d after immunization), whereas looking at this earlier time point identified clear differences. By the latter time point, antibody titers had fallen, removing differences between the groups that were present at the time of peak levels. This is an important technical point on the use of this model. Several time points need to be assessed before concluding that there are no differences in antibody levels. The findings in the serum were supported by a similar pattern of IgG subclass deposition within the glomerulus at day 14. In the glomerulus, there was a greater deposition of IgG2b and IgG3 but not IgG1 despite higher levels of antigen- Figure 5 . (A) Serum titers of murine IgG subclasses against sheep IgG at 5, 9, and 14 d after disease induction in wild-type mice that were immunized with and without lipopeptide compared with levels that were seen in normal mouse serum. There are significantly greater levels of antigen-specific IgG1, IgG2b, and IgG3 in the mice that were immunized with lipopeptide at 5 d after disease induction (P ϭ 0.0304, P ϭ 0.0063, and P ϭ 0.0106, respectively). These differences are not seen at any other time point. There are no significant differences in the antigen-specific IgG2a levels at any time point after disease induction. (B) Glomerular CD4 T cell infiltration in wild-type mice that were immunized with and without lipopeptide. Significantly greater numbers of glomerular T cells are seen in the mice that were immunized with lipopeptide (P ϭ 0.0028). (C) Peroxidase staining for CD4 to show glomerular CD4 T cell infiltration at 14 d after disease induction in wild-type mice that were immunized with and without lipopeptide. Greater numbers are seen in the glomeruli of the mice that were immunized with lipopeptide (right) compared with the mice that were not immunized with lipopeptide (left).
specific IgG1 in the serum at 5 d. This probably reflects differences in the sensitivity of the two methods, because the ELISA would be expected to be more sensitive. We also demonstrated an increase in CD4-positive T cell numbers in the glomeruli of mice that were immunized with lipopeptide. These findings suggest that an increase in both humoral and cell-mediated immunity contributes to the increase in disease severity seen.
Similar models of glomerulonephritis have been used extensively to dissect out mechanisms of glomerular injury. When sensitized C57BL/6 mice are given a heterologous nephrotoxic serum, they develop a predominant Th1-type response. Depletion of CD4 ϩ T cells at disease induction and treatment with anti-IFN-␥ antibody were associated with a reduction in disease severity (30) , showing that disease in this model is influenced by the Th1/Th2 balance. Although some have suggested that this model is antibody independent (31), others have shown Fc receptor dependence (32) , implicating antibody in disease pathogenesis. It therefore is not clear whether the Th1 predominance reflects an altered role for the effector CD4 T cells or a shift toward more pathogenic IgG subclasses. In other models of glomerulonephritis, TLR ligands have been shown to exacerbate disease. It has been shown that endotoxin exacerbates disease in the heterologous phase of nephrotoxic nephritis (33) (34) (35) . These studies use crude endotoxin preparations that are known to contain ligands for both TLR2 and TLR4 (36) and therefore do not dissect out the precise role for each receptor. Heterologous nephrotoxic nephritis is a model of acute glomerular inflammation; therefore, the disease exacerbation that was seen in this model is related to an effect on innate immunity and cannot be mechanistically attributed to any influence on the adaptive immune response. Figure 6 . Glomerular deposition of murine IgG subclasses, as measured by mean glomerular immunofluorescence at 14 d after disease induction in wild-type and TLR2-deficient mice that were immunized with and without lipopeptide. There is no significant difference in the amount of IgG1 deposited among the groups (A). There is a significantly larger amount of IgG2b deposition in the wild-type mice that were given lipopeptide when compared with mice that were not given lipopeptide (P Ͻ 0.05; B). There is significantly greater IgG3 deposition in the wild-type mice that were immunized with lipopeptide when compared with mice that were not immunized with lipopeptide and TLR2-deficient mice that were immunized with lipopeptide (P Ͻ 0.05; C). (D) Representative samples from immunofluorescence for deposition of IgG2b and IgG3 in wild-type and TLR2-deficient mice that were immunized with or without lipopeptide.
In models of chronic glomerular disease, viral doublestranded RNA, a known TLR3 ligand, and bacterial DNA, a TLR9 ligand, have been shown to aggravate lupus nephritis (37, 38) . Bacterial DNA also has been shown to aggravate horse apoferritin-induced glomerulonephritis. Disease exacerbation in this immune complex-mediated renal injury was associated with characteristics of a predominant Th1-type response (39) . Although known TLR ligands were used, none of the above studies directly demonstrated that specific TLR were responsible for the observed effects, because knockout mice were not used. The present studies directly show that a specific TLR ligand can influence disease severity by an effect on the adaptive immune response.
TLR have been implicated in the link between innate and adaptive immunity. It initially was thought that immune recognition and activation via TLR in vivo promoted a predominant Th1 effector response, and Th2 responses seemed to be independent of TLR signaling (8) . Since then, it has been shown that dendritic cells display different responses when exposed to different TLR agonists in vitro (7) . In particular, stimulation of dendritic cells by LPS promoted a predominant Th1 response, whereas lipopeptide promoted a Th2 bias. Using an experimental model of asthma, the effect of TLR4 ligands on disease severity was assessed by immunizing animals intranasally with ovalbumin that was given either alone or with low-or high-dose LPS. It is interesting that the low doses of LPS encouraged a predominant Th2-type response and tissue infiltration with eosinophils, whereas those that were given the higher dose produced a Th1 response and lung infiltration with neutrophils (12) . When lipopeptide is used as an adjuvant with ovalbumin, it can exacerbate experimental asthma and produce an associated systemic Th2 response, which, unlike LPS, is not dose dependent (13) . Another study investigated the effect of TLR2 agonists on established airway inflammation and discovered that lipopeptide actually attenuated disease, and this was associated with an increase in IFN-␥ and therefore predominant Th1-type response (11) . The route of exposure to a given ligand has been shown to be important in influencing the immune response. When C57BL/6 animals were exposed intranasally to Leishmania major, which contains numerous TLR ligands, there was generation of a Th2 predominance, whereas when they were exposed subcutaneously, a strong Th1-type response was produced (40) .
There are many factors that affect the modulation of the adaptive immune response after exposure to pathogens. Not only the specific TLR ligand to which an organism is exposed is important but also the dose of the ligand, the timing of administration in relation to sensitization, and the route of exposure. In this study, we show that TLR ligands, when administered at immunization, can influence the development of glomerular disease. The administration of the synthetic lipopeptide Pam 3 CysSK 4 can influence profoundly disease severity in accelerated nephrotoxic nephritis, and this is entirely TLR2 dependent. We have also suggested a potential mechanism for this by showing that there is an increased CD4 ϩ T cell infiltrate and elevated levels of antigen-specific IgG1, IgG2b, and IgG3. These findings give a potential mechanism by which systemic infections may influence glomerulonephritis, and TLR2 blockade may be a useful therapeutic maneuver in the prevention of disease.
